#StemRIM

StemRim announced the registration of a patent in Canada for Ledasemide, aiming to expand its application to cardiomyopathy and heart failure. Since March 2024, a Phase II physician-led clinical trial has been initiated with Osaka University Graduate School of Medicine.

Notice of patent registration for the stem cell gene therapy technology SR-GT1 related to treatment for nutritional epidermolysis bullosa completed in Korea. Disclosure of basic information such as invention title, jurisdiction, application number, and applicant.

Ukraine? Note: Please provide accurate official English name and context. Translation attempted: A patent covering the use of redasemtide for fatty liver/NASH is expected to be registered in Russia. Applicants are StemRim, Osaka University, and Niigata University. No impact on the full-year results for the fiscal year ending July 2026. Future expansion of applications is insured.